je.st
news
Tag: drug administration
CASMED Receives China Food and Drug Administration Approval for FORE-SIGHT® Cerebral ...
2013-11-25 06:00:00| Industrial Newsroom - All News for Today
FORE-SIGHT Becomes the Only Foreign-Made Cerebral Oximeter Approved in China<br /> <br /> BRANFORD, Conn. — CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, today announced that its FORE-SIGHT Cerebral Oximeter has been approved by the China Food and Drug Administration (CFDA) for sale in that country. FORE-SIGHT is the only cerebral oximeter manufactured outside China to have approval from the CDFA.<br /> <br /> "The CFDA ...This story is related to the following:Sensors, Monitors and TransducersPatient Monitoring Equipment | Oxygen Meters
Tags: china
food
administration
drug
U.S. Department of Justice and Drug Enforcement Administration - National Drug Threat Assessment Summary 2013
2013-11-22 01:06:23| PortlandOnline
Tags: national
department
summary
administration
The US Food and Drug Administration is looking to ban artificial trans fat in processed food.
2013-11-08 11:51:02| Food - Topix.net
The US Food and Drug Administration is looking to ban artificial trans fat in processed food such as hot chips.
Tags: food
administration
drug
fat
Vertex Submits Supplemental New Drug Application (sNDA) To U.S. Food And Drug Administration For KALYDECO (ivacaftor) Monotherapy For People With Non-G551D Gating Mutations
2013-10-02 05:50:27| drugdiscoveryonline News Articles
Vertex Pharmaceuticals Incorporated recently announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of KALYDECOTM (ivacaftor) monotherapy for people with cystic fibrosis (CF) ages 6 and older who have at least one non-G551D gating mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Tags: with
people
food
application
U.S. Food and Drug Administration Approves ABRAXANE in Combination...
2013-09-07 09:04:00| Biotech - Topix.net
Celgene Corporation today announced that the U.S. Food and Drug Administration has approved the Company's supplemental New Drug Application of ABRAXANEA as first-line treatment for patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Tags: food
administration
combination
drug